NO332474B1 - Anvendelse av et preparat omfattende konjugert linolsyre - Google Patents
Anvendelse av et preparat omfattende konjugert linolsyre Download PDFInfo
- Publication number
- NO332474B1 NO332474B1 NO20005566A NO20005566A NO332474B1 NO 332474 B1 NO332474 B1 NO 332474B1 NO 20005566 A NO20005566 A NO 20005566A NO 20005566 A NO20005566 A NO 20005566A NO 332474 B1 NO332474 B1 NO 332474B1
- Authority
- NO
- Norway
- Prior art keywords
- cla
- isomers
- diet
- isomer
- preparation
- Prior art date
Links
- 229940108924 conjugated linoleic acid Drugs 0.000 title claims abstract description 172
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 title claims abstract description 20
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 title claims abstract 4
- 239000000203 mixture Substances 0.000 title abstract description 31
- 238000002360 preparation method Methods 0.000 claims abstract description 41
- 210000000577 adipose tissue Anatomy 0.000 claims description 18
- 235000021588 free fatty acids Nutrition 0.000 claims description 14
- 125000005907 alkyl ester group Chemical group 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- ADHNUPOJJCKWRT-JLXBFWJWSA-N (2e,4e)-octadeca-2,4-dienoic acid Chemical compound CCCCCCCCCCCCC\C=C\C=C\C(O)=O ADHNUPOJJCKWRT-JLXBFWJWSA-N 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 17
- 235000016709 nutrition Nutrition 0.000 abstract description 9
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 230000000144 pharmacologic effect Effects 0.000 abstract description 4
- 235000005911 diet Nutrition 0.000 description 44
- 230000037213 diet Effects 0.000 description 42
- 241001465754 Metazoa Species 0.000 description 35
- 241000699670 Mus sp. Species 0.000 description 21
- 235000019197 fats Nutrition 0.000 description 19
- 235000013305 food Nutrition 0.000 description 19
- 230000009467 reduction Effects 0.000 description 16
- 241000287828 Gallus gallus Species 0.000 description 14
- 235000013330 chicken meat Nutrition 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 241000030538 Thecla Species 0.000 description 13
- 241000282412 Homo Species 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 235000020778 linoleic acid Nutrition 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 125000004494 ethyl ester group Chemical group 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- JBYXPOFIGCOSSB-XBLVEGMJSA-N 9E,11E-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C\CCCCCCCC(O)=O JBYXPOFIGCOSSB-XBLVEGMJSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 241000282887 Suidae Species 0.000 description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 235000020940 control diet Nutrition 0.000 description 8
- 238000006317 isomerization reaction Methods 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- 239000003513 alkali Substances 0.000 description 7
- 150000003626 triacylglycerols Chemical class 0.000 description 7
- 230000004584 weight gain Effects 0.000 description 7
- 235000019786 weight gain Nutrition 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 235000015872 dietary supplement Nutrition 0.000 description 5
- 238000004817 gas chromatography Methods 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 description 5
- 208000016261 weight loss Diseases 0.000 description 5
- 230000004580 weight loss Effects 0.000 description 5
- 241000605900 Butyrivibrio fibrisolvens Species 0.000 description 4
- 241000700198 Cavia Species 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 235000019485 Safflower oil Nutrition 0.000 description 4
- 235000019486 Sunflower oil Nutrition 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000002285 corn oil Substances 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 235000005713 safflower oil Nutrition 0.000 description 4
- 239000003813 safflower oil Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000002600 sunflower oil Substances 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 102000003390 tumor necrosis factor Human genes 0.000 description 4
- GKJZMAHZJGSBKD-UHFFFAOYSA-N (10E,12E)-Octadeca-9,11-dienoic acid Natural products CCCCCC=CC=CCCCCCCCCC(O)=O GKJZMAHZJGSBKD-UHFFFAOYSA-N 0.000 description 3
- GKJZMAHZJGSBKD-BLHCBFLLSA-N (10e,12e)-octadeca-10,12-dienoic acid Chemical compound CCCCC\C=C\C=C\CCCCCCCCC(O)=O GKJZMAHZJGSBKD-BLHCBFLLSA-N 0.000 description 3
- GKJZMAHZJGSBKD-ANYPYVPJSA-N 10-trans-12-cis-linoleic acid Natural products CCCCCC=C\C=C\CCCCCCCCC(O)=O GKJZMAHZJGSBKD-ANYPYVPJSA-N 0.000 description 3
- 244000020518 Carthamus tinctorius Species 0.000 description 3
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 239000004367 Lipase Substances 0.000 description 3
- 108090001060 Lipase Proteins 0.000 description 3
- 102000004882 Lipase Human genes 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 241000282849 Ruminantia Species 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000004820 blood count Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 229960004106 citric acid Drugs 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 235000005687 corn oil Nutrition 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 235000019421 lipase Nutrition 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 150000004671 saturated fatty acids Chemical class 0.000 description 3
- 235000003441 saturated fatty acids Nutrition 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 235000008522 spreadable oils and fats Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000003437 trachea Anatomy 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 102000004195 Isomerases Human genes 0.000 description 2
- 108090000769 Isomerases Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 150000004668 long chain fatty acids Chemical class 0.000 description 2
- 238000006140 methanolysis reaction Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 235000021485 packed food Nutrition 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 102100027324 2-hydroxyacyl-CoA lyase 1 Human genes 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000016444 Benign adult familial myoclonic epilepsy Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 101001009252 Homo sapiens 2-hydroxyacyl-CoA lyase 1 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 241001661345 Moesziomyces antarcticus Species 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010040030 Sensory loss Diseases 0.000 description 1
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 241000482268 Zea mays subsp. mays Species 0.000 description 1
- GHVZOJONCUEWAV-UHFFFAOYSA-N [K].CCO Chemical compound [K].CCO GHVZOJONCUEWAV-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000019728 animal nutrition Nutrition 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 238000006701 autoxidation reaction Methods 0.000 description 1
- 235000014590 basal diet Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000003043 biohydrogenation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000015223 cooked beef Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000016427 familial adult myoclonic epilepsy Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000004459 forage Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 235000006486 human diet Nutrition 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 235000020888 liquid diet Nutrition 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- 210000000207 lymphocyte subset Anatomy 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000020786 mineral supplement Nutrition 0.000 description 1
- 229940029985 mineral supplement Drugs 0.000 description 1
- 238000000199 molecular distillation Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- JGFMXQLVWUGIPI-UHFFFAOYSA-N octadeca-11,13-dienoic acid Chemical compound CCCCC=CC=CCCCCCCCCCC(O)=O JGFMXQLVWUGIPI-UHFFFAOYSA-N 0.000 description 1
- ADHNUPOJJCKWRT-UHFFFAOYSA-N octadeca-2,4-dienoic acid Chemical compound CCCCCCCCCCCCCC=CC=CC(O)=O ADHNUPOJJCKWRT-UHFFFAOYSA-N 0.000 description 1
- PJSQIDIRJGWHOB-UHFFFAOYSA-N octadeca-4,6-dienoic acid Chemical compound CCCCCCCCCCCC=CC=CCCC(O)=O PJSQIDIRJGWHOB-UHFFFAOYSA-N 0.000 description 1
- CNKMVAJDUBKHMS-UHFFFAOYSA-N octadeca-6,8-dienoic acid Chemical compound CCCCCCCCCC=CC=CCCCCC(O)=O CNKMVAJDUBKHMS-UHFFFAOYSA-N 0.000 description 1
- HACBQSMIIGXKGA-UHFFFAOYSA-N octadeca-7,9-dienoic acid Chemical compound CCCCCCCCC=CC=CCCCCCC(O)=O HACBQSMIIGXKGA-UHFFFAOYSA-N 0.000 description 1
- QJKCKUNKNNYJNS-UHFFFAOYSA-N octadeca-8,10-dienoic acid Chemical compound CCCCCCCC=CC=CCCCCCCC(O)=O QJKCKUNKNNYJNS-UHFFFAOYSA-N 0.000 description 1
- -1 octadecadiene fatty acid Chemical class 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 231100000272 reduced body weight Toxicity 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- 235000014438 salad dressings Nutrition 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 231100001055 skeletal defect Toxicity 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009959 type I hypersensitivity Effects 0.000 description 1
- 238000009489 vacuum treatment Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
- C11C3/00—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom
- C11C3/04—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fats or fatty oils
- C11C3/10—Ester interchange
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B3/00—Refining fats or fatty oils
- C11B3/001—Refining fats or fatty oils by a combination of two or more of the means hereafter
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
- C11C1/00—Preparation of fatty acids from fats, fatty oils, or waxes; Refining the fatty acids
- C11C1/02—Preparation of fatty acids from fats, fatty oils, or waxes; Refining the fatty acids from fats or fatty oils
- C11C1/025—Preparation of fatty acids from fats, fatty oils, or waxes; Refining the fatty acids from fats or fatty oils by saponification and release of fatty acids
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
- C11C3/00—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom
- C11C3/02—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fatty acids with glycerol
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
- C11C3/00—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom
- C11C3/14—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by isomerisation
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Animal Husbandry (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Fats And Perfumes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/072,421 US6214372B1 (en) | 1998-05-04 | 1998-05-04 | Method of using isomer enriched conjugated linoleic acid compositions |
| US09/072,422 US6060514A (en) | 1998-05-04 | 1998-05-04 | Isomer enriched conjugated linoleic acid compositions |
| PCT/US1999/005808 WO1999056781A1 (fr) | 1998-05-04 | 1999-03-17 | Procedes d'utilisation de compositions d'acides linoleiques conjugues, enrichies en isomeres |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20005566D0 NO20005566D0 (no) | 2000-11-03 |
| NO20005566L NO20005566L (no) | 2001-01-03 |
| NO332474B1 true NO332474B1 (no) | 2012-09-24 |
Family
ID=26753359
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20005565A NO332473B1 (no) | 1998-05-04 | 2000-11-03 | Preparat med konjugert linolsyre |
| NO20005566A NO332474B1 (no) | 1998-05-04 | 2000-11-03 | Anvendelse av et preparat omfattende konjugert linolsyre |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20005565A NO332473B1 (no) | 1998-05-04 | 2000-11-03 | Preparat med konjugert linolsyre |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US6225486B1 (fr) |
| EP (2) | EP0954983B1 (fr) |
| JP (12) | JP2001508812A (fr) |
| KR (2) | KR100402040B1 (fr) |
| AT (2) | ATE366521T1 (fr) |
| AU (2) | AU747058B2 (fr) |
| CA (2) | CA2293338C (fr) |
| DE (2) | DE69936484T2 (fr) |
| DK (2) | DK0954983T3 (fr) |
| ES (2) | ES2286867T3 (fr) |
| IN (1) | IN214289B (fr) |
| MX (2) | MX234917B (fr) |
| NO (2) | NO332473B1 (fr) |
| WO (2) | WO1999056780A1 (fr) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7101914B2 (en) * | 1998-05-04 | 2006-09-05 | Natural Asa | Isomer enriched conjugated linoleic acid compositions |
| FR2784268B1 (fr) * | 1998-10-12 | 2000-12-29 | Gervais Danone Sa | Nouvelle composition alimentaire, a base de matiere issue du lait, sous la forme d'une emulsion huile dans eau |
| GB9828380D0 (en) * | 1998-12-22 | 1999-02-17 | Unilever Plc | Skin lightening composition |
| US6020378A (en) * | 1999-03-30 | 2000-02-01 | Wisconsin Alumni Research Foundation | Method for selectively altering body fat level, feed efficiently, or weight gain |
| AU3843200A (en) * | 1999-04-27 | 2000-11-10 | Kabushiki Kaisha Yakult Honsha | Conjugated fatty acid esters |
| US6420577B1 (en) * | 1999-12-01 | 2002-07-16 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture | Method for commercial preparation of conjugated linoleic acid |
| JP4262382B2 (ja) * | 2000-02-03 | 2009-05-13 | 株式会社ヤクルト本社 | 共役脂肪酸グリセリド含有発酵食品及びその製造法 |
| WO2001060331A2 (fr) * | 2000-02-15 | 2001-08-23 | Zen-Bio, Inc. | Compositions destinees a prevenir la cellulite chez un mammifere |
| CA2404799C (fr) * | 2000-04-06 | 2007-08-07 | Conlinco, Inc. | Compositions d'acide linoleique conjugue |
| US6756405B2 (en) * | 2000-04-18 | 2004-06-29 | Natural Asa | Conjugated linoleic acid powder |
| US20030149288A1 (en) * | 2000-04-18 | 2003-08-07 | Natural Asa | Conjugated linoleic acid powder |
| US6380409B1 (en) * | 2000-04-24 | 2002-04-30 | Conlin Co., Inc. | Methods for preparing CLA isomers |
| US7025984B1 (en) * | 2000-06-26 | 2006-04-11 | The Procter & Gamble Company | Compositions and methods for body weight management |
| AU2005242170B2 (en) * | 2000-06-26 | 2008-12-18 | The Procter & Gamble Company | Compositions and methods for body weight management |
| EP1357977B1 (fr) * | 2000-09-21 | 2004-07-21 | Nutrition 21, Inc. | Compositions contenant du chrome pour le traitement du diabete, la reduction des graisses corporelles, l'amelioration de la sensibilite a l'insuline, la reduction de l'hyperglycemie et la reduction de l'hypercholesterolemie. |
| WO2002041706A2 (fr) * | 2000-11-21 | 2002-05-30 | Alpha Foods Ingredients, Inc. | Glycerides bioactifs d'acide linoleique conjugue et procede d'utilisation |
| GB0105622D0 (en) * | 2001-03-07 | 2001-04-25 | Natural Asa | Compositions |
| AU2002257714B2 (en) * | 2001-03-29 | 2007-06-28 | Basf Aktiengesellschaft | Conjugated unsaturated glyceride mixtures and a method for producing the same |
| KR20020081632A (ko) * | 2001-04-19 | 2002-10-30 | (주)라이브맥스 | Ｃｌａ가 함유된 재구성 지질의 제조방법 및 이용방법 |
| US6677470B2 (en) | 2001-11-20 | 2004-01-13 | Natural Asa | Functional acylglycerides |
| DE10158046A1 (de) * | 2001-11-27 | 2003-06-05 | Basf Ag | Formulierung für den Einsatz in Lebensmitteln, Nahrungsergänzungsmitteln, Futtermitteln, Futterzusatzstoffen, pharmazeutischen und kosmetischen Zubereitungen sowie Verfahren zu deren Herstellung |
| WO2003061402A2 (fr) * | 2002-01-22 | 2003-07-31 | Mars, Incorporated | Limitation des affections renales chez les animaux de compagnie |
| US20030138547A1 (en) * | 2002-01-22 | 2003-07-24 | Mars, Incorporated | Weight management system for animals |
| DE10219781A1 (de) * | 2002-05-03 | 2003-11-13 | Cognis Deutschland Gmbh | Verfahren zur Herstellung von konjugierten Linolsäureglyceriden |
| DE10236086A1 (de) * | 2002-08-07 | 2004-02-19 | Cognis Deutschland Gmbh & Co. Kg | Verfahren zur Herstellung von konjugierter Linolsäure |
| US20040044079A1 (en) * | 2002-09-04 | 2004-03-04 | The Iams Company | Methods and compositions for weight control |
| US7244874B2 (en) * | 2002-09-17 | 2007-07-17 | The Regents Of The University Of California | Stearoyl CoA desaturase transgenic non-human animals |
| US6743931B2 (en) * | 2002-09-24 | 2004-06-01 | Natural Asa | Conjugated linoleic acid compositions |
| US20040229950A1 (en) * | 2002-11-26 | 2004-11-18 | Vanderhoek Jack Y. | Method and composition with conjugated linoleic acid esters |
| JP4510045B2 (ja) * | 2003-01-31 | 2010-07-21 | 日清オイリオグループ株式会社 | 共役リノール酸異性体の精製方法およびその用途 |
| JP2004248671A (ja) * | 2003-01-31 | 2004-09-09 | Rinoru Oil Mills Co Ltd | 共役リノール酸異性体の精製方法およびその用途 |
| WO2004096748A1 (fr) * | 2003-04-25 | 2004-11-11 | Ilshinwells Co., Ltd. | Procede de preparation de diglycerides d'acide linoleique conjugue |
| US6897327B2 (en) * | 2003-05-08 | 2005-05-24 | Stepan Company | Manufacture of conjugated linoleic salts and acids |
| US20040228948A1 (en) * | 2003-05-16 | 2004-11-18 | Kennelly John J. | Increasing the concentration of conjugated linoleic acid isomers in the milk fat and/or tissue fat of ruminants |
| US20050069593A1 (en) * | 2003-09-29 | 2005-03-31 | Life Time Fitness, Inc. | Nutritional supplement containing 7-Keto-DHEA and conjugated linoleic acid |
| EP1541040A1 (fr) * | 2003-12-04 | 2005-06-15 | Cognis Iberia S.L | Composition pour administration orale (VI) comprenant un extrait ou des agents actifs de Medicago sativa |
| US20070191619A1 (en) * | 2003-12-23 | 2007-08-16 | Stepan Company | Production and purification of esters of conjugated linoleic acids |
| EP1729851A2 (fr) | 2004-03-10 | 2006-12-13 | Natural ASA | Compositions comportant des isomeres inverses d'acide linoleique conjugue |
| US7767713B2 (en) * | 2004-08-05 | 2010-08-03 | Palo Alto Investors | Linoleic acid active agents for enhancing probability of becoming pregnant |
| EP1627565A1 (fr) * | 2004-08-10 | 2006-02-22 | Consejo Superior de Investigaciones Cientificas (CSIC) | Utilisation de dérivés du flavanol pour la cryoconservation de cellules vivantes |
| ES2258928A1 (es) * | 2005-02-25 | 2006-09-01 | Aceites Borges Pont, S.A. | Composicion a base de aceites vegetales y acido linoleico conjugado. |
| US8203012B2 (en) * | 2005-12-05 | 2012-06-19 | Stepan Company | Process for preparing conjugated linoleic acid and derivatives thereof from ricinoleic acid |
| EP2004784B1 (fr) * | 2006-04-13 | 2014-01-08 | Stepan Specialty Products, LLC | Procédé de production de préparations d'acide linéoléique conjugué enrichies en isomères |
| JP5099808B2 (ja) * | 2006-05-29 | 2012-12-19 | 独立行政法人農業・食品産業技術総合研究機構 | 脂質代謝改善用組成物 |
| DE102007009649A1 (de) * | 2007-02-26 | 2008-08-28 | Beiersdorf Ag | Nahrungsergänzungsmittel zur Pflege und/oder Verschönerung der Haut |
| JP2008237032A (ja) * | 2007-03-23 | 2008-10-09 | Ezaki Glico Co Ltd | 高嗜好性食品 |
| WO2008128767A2 (fr) * | 2007-04-24 | 2008-10-30 | Lipid Nutrition B.V. | Yogourt à faible teneur en sucre |
| KR100809411B1 (ko) * | 2007-08-31 | 2008-03-05 | (주)에이치케이바이오텍 | 체지방감소용 조성물 |
| ES2430200T3 (es) * | 2007-10-29 | 2013-11-19 | Stepan Specialty Products, Llc | Composición de aderezo |
| KR101482775B1 (ko) * | 2010-08-25 | 2015-01-16 | 이화여자대학교 산학협력단 | 운데실렌산 및/또는 공액리놀렌산을 포함하는 퇴행성 신경질환의 예방 또는 치료용 조성물 |
| WO2012026663A1 (fr) * | 2010-08-25 | 2012-03-01 | 이화여자대학교 산학협력단 | Complément anticancéreux comprenant un acide undécylénique, un acide linoléique conjugué, et/ou un isomère de l'acide linoléique conjugué |
| EP2983658B1 (fr) | 2013-03-11 | 2024-05-01 | Sciadonics, Inc. | Compositions lipidiques contenant des acides gras bioactifs |
| CN106102475A (zh) * | 2014-03-13 | 2016-11-09 | 巴斯夫欧洲公司 | 富含瘤胃不稳定成分的颗粒的反刍动物饲料 |
| KR101907438B1 (ko) * | 2016-12-08 | 2018-10-15 | 현대오트론 주식회사 | 차량용 게이트웨이의 주기 메시지 송수신 방법 |
| CN112451512A (zh) * | 2020-11-26 | 2021-03-09 | 青海省人民医院 | 一种药物组合物及其治疗骨质疏松的用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3729379A (en) | 1971-08-31 | 1973-04-24 | Us Agriculture | Hydroxy-conjugated fatty acids |
| US4164505A (en) | 1977-07-08 | 1979-08-14 | Sylvachem Corporation | Flow process for conjugating unconjugated unsaturation of fatty acids |
| US5208356A (en) | 1989-02-17 | 1993-05-04 | Wisconsin Alumni Research Foundation | Octadecadienoic phospholipic esters, antioxidant and mold inhibiting compositions |
| GB2240051B (en) | 1990-01-18 | 1993-04-14 | Pall Corp | Cylindrical filters and their manufacture |
| US5674901A (en) | 1995-06-01 | 1997-10-07 | Wisconsin Alumni Research Foundation | Methods of treating animals to maintain or increase CD-4 and CD-8 cell populations |
| US5430066A (en) * | 1992-04-29 | 1995-07-04 | Wisconsin Alumni Research Foundation | Methods for preventing weight loss, reduction in weight gain, and anorexia due to immune stimulation |
| US5554646A (en) * | 1992-04-29 | 1996-09-10 | Wisconsin Alumni Research Foundation | Method for reducing body fat in animals |
| US5428072A (en) * | 1992-04-29 | 1995-06-27 | Wisconsin Alumni Research Foundation | Method of increasing the efficiency of feed conversion in animals |
| US5814663A (en) * | 1994-08-29 | 1998-09-29 | Wisconsin Alumni Research Foundation | Method for maintaining an existing level of body fat |
| US5760082C1 (en) | 1994-08-29 | 2001-03-06 | Wisconsin Alumni Res Found | Dietetic foods containing conjugated linoleic acids |
| US5856149A (en) | 1995-06-01 | 1999-01-05 | Wisconsin Alumni Research Foundation | Method of producing conjugated fatty acids |
| EP0779033B1 (fr) | 1995-11-14 | 2001-09-26 | Unilever N.V. | Produit à tartiner comestible |
| DE69609196T3 (de) * | 1995-11-14 | 2006-01-26 | Loders Croklaan B.V. | Verfahren zur Herstellung von Materialien mit hohem Gehalt an isomeren von konjugierter Linolsäure |
| US5585400A (en) | 1996-02-27 | 1996-12-17 | Wisconsin Alumni Research Foundation | Methods of attenuating the allergic response in animals |
| US5760083A (en) | 1996-08-07 | 1998-06-02 | Wisconsin Alumni Research Foundation | Use of CLA to reduce the incidence of valgus and varus leg deforomities in poultry |
| US5804210A (en) | 1996-08-07 | 1998-09-08 | Wisconsin Alumni Research Foundation | Methods of treating animals to maintain or enhance bone mineral content and compositions for use therein |
| JP3017108B2 (ja) | 1996-10-30 | 2000-03-06 | リノール油脂株式会社 | 共役リノール酸の製造方法 |
| US5855917A (en) | 1996-12-04 | 1999-01-05 | Wisconsin Alumni Research Foundation | Method for controlling body fat and/or body weight in animals and pharmaceutical compositions for use therein comprising 20-carbon conjugated unsaturated fatty acids |
| US5851572A (en) | 1997-04-25 | 1998-12-22 | Wisconsin Alumni Research Foundation | Method of increasing fat firmness and improving meat quality in animals with conjugated linolenic acid |
| DE19718245C5 (de) | 1997-04-30 | 2004-11-11 | Cognis Deutschland Gmbh & Co. Kg | Synthetische Triglyceride auf Basis konjugierter Linolsäure, Verfahren zu deren Herstellung und deren Verwendung |
| SE9704584L (sv) * | 1997-12-05 | 1999-07-19 | Lennart Bjoerck | Framställning av konjugerad linolsyra |
| US6015833A (en) | 1998-03-17 | 2000-01-18 | Conlinco., Inc. | Conjugated linoleic acid compositions |
-
1999
- 1999-03-17 WO PCT/US1999/005807 patent/WO1999056780A1/fr not_active Application Discontinuation
- 1999-03-17 MX MXPA00010794 patent/MX234917B/es active IP Right Grant
- 1999-03-17 AT AT99105495T patent/ATE366521T1/de not_active IP Right Cessation
- 1999-03-17 IN IN487KO2000 patent/IN214289B/en unknown
- 1999-03-17 DK DK99105495T patent/DK0954983T3/da active
- 1999-03-17 CA CA002293338A patent/CA2293338C/fr not_active Expired - Fee Related
- 1999-03-17 AU AU30953/99A patent/AU747058B2/en not_active Ceased
- 1999-03-17 CA CA002293336A patent/CA2293336C/fr not_active Expired - Fee Related
- 1999-03-17 AT AT99105496T patent/ATE313274T1/de not_active IP Right Cessation
- 1999-03-17 WO PCT/US1999/005808 patent/WO1999056781A1/fr active IP Right Grant
- 1999-03-17 DE DE69936484T patent/DE69936484T2/de not_active Expired - Lifetime
- 1999-03-17 AU AU30083/99A patent/AU747057B2/en not_active Ceased
- 1999-03-17 JP JP55536299A patent/JP2001508812A/ja not_active Withdrawn
- 1999-03-17 EP EP99105495A patent/EP0954983B1/fr not_active Expired - Lifetime
- 1999-03-17 EP EP99105496A patent/EP0954975B1/fr not_active Expired - Lifetime
- 1999-03-17 DE DE69928986T patent/DE69928986T2/de not_active Expired - Lifetime
- 1999-03-17 ES ES99105495T patent/ES2286867T3/es not_active Expired - Lifetime
- 1999-03-17 KR KR20007012218A patent/KR100402040B1/ko not_active IP Right Cessation
- 1999-03-17 KR KR1020007012280A patent/KR100655838B1/ko not_active IP Right Cessation
- 1999-03-17 DK DK99105496T patent/DK0954975T3/da active
- 1999-03-17 US US09/270,941 patent/US6225486B1/en not_active Expired - Lifetime
- 1999-03-17 JP JP55536399A patent/JP2001508085A/ja active Pending
- 1999-03-17 MX MXPA00010793 patent/MX228618B/es active IP Right Grant
- 1999-03-17 ES ES99105496T patent/ES2255741T3/es not_active Expired - Lifetime
-
2000
- 2000-11-03 NO NO20005565A patent/NO332473B1/no not_active IP Right Cessation
- 2000-11-03 NO NO20005566A patent/NO332474B1/no not_active IP Right Cessation
-
2001
- 2001-01-30 US US09/772,608 patent/US6333353B2/en not_active Expired - Lifetime
- 2001-12-17 JP JP2001383829A patent/JP2002223722A/ja active Pending
-
2002
- 2002-06-27 JP JP2002188786A patent/JP2003047439A/ja active Pending
- 2002-06-27 JP JP2002188788A patent/JP2003113080A/ja active Pending
-
2003
- 2003-05-08 JP JP2003130313A patent/JP2003319759A/ja active Pending
-
2010
- 2010-05-25 JP JP2010119795A patent/JP2010195825A/ja not_active Withdrawn
- 2010-05-25 JP JP2010119924A patent/JP2010259437A/ja not_active Withdrawn
-
2013
- 2013-02-13 JP JP2013025421A patent/JP2013106613A/ja not_active Withdrawn
- 2013-03-18 JP JP2013054623A patent/JP2013165717A/ja not_active Withdrawn
-
2014
- 2014-09-16 JP JP2014187525A patent/JP2015037410A/ja active Pending
- 2014-09-16 JP JP2014187486A patent/JP2015044810A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU747058B2 (en) | Isomer enriched conjugated linoleic acid compositions | |
| US7094420B2 (en) | Methods of using isomer enriched conjugated linoleic acid compositions | |
| US6060514A (en) | Isomer enriched conjugated linoleic acid compositions | |
| AU2001257627B2 (en) | Methods for preparing cla isomers | |
| US7101914B2 (en) | Isomer enriched conjugated linoleic acid compositions | |
| US6696584B2 (en) | Isomer enriched conjugated linoleic acid compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |